25/04/2026
Developing new medicines is complex, costly, and time-consuming. At myriamed GmbH, based in Göttingen, Germany, we help drug developers make better decisions earlier — using advanced human stem-cell-derived 3D tissue models that simulate health and disease directly in the dish. myriamed’s engineered tissue platforms are designed to support early drug discovery, candidate refinement, safety assessment, and dose definition for first-in-human studies.
At the core of this approach is myrTissue-Cardio: bioengineered human cardiac tissue derived from iPS cells. These 3D heart muscle models beat rhythmically, mimic key features of human myocardium, and enable highly relevant functional testing of drug candidates in a human-based system.
Now, myriamed takes this technology one step further with the powerful combination of myrPlates and myrImager.
🧫 myrPlates are 48-well 3D cell and tissue culture plates designed for the construction and long-term culture of engineered tissues. Each well contains flexible stretchers that support tissue formation in a ring format under defined mechanical load. The stretchers include fluorescent markers for optical tracing of mechanical forces generated by the tissue.
📸 myrImager is a state-of-the-art automated imaging and analysis platform developed for use with myrPlates. It enables non-invasive, high-precision, high-throughput analysis of cardiac tissue function — without direct cell imaging — and is designed for laboratories in research, biotechnology, and pharmaceuticals.
Together, myrPlates + myrImager create a comprehensive solution for using engineered human tissues in drug development:
✅ Functional analysis of 3D cardiac tissue
✅ Reproducible high-throughput screening
✅ Longitudinal measurements over time
✅ Human-relevant insights into efficacy and safety
✅ Reduced reliance on animal testing
✅ Better prediction of drug effects before clinical trials
This combination makes it possible to evaluate drug candidates on human-like tissue responses earlier, faster, and with greater physiological relevance — helping researchers identify promising compounds and detect potential risks before they reach patients.
Beyond cardiac tissue, myriamed also develops advanced 3D models for skeletal muscle and brain research, supporting a broader vision: accelerating personalized medicine and making drug development more predictive, ethical, and efficient.
📍 myriamed GmbH
Rudolf-Wissell-Straße 28a
37079 Göttingen, Germany
📞 +49 551 2887817 0
www.myriamed.com
[email protected]
➡️ myriamed – testing the future of medicine. Today. 🧪✨
